Abstract:Leber congenital amaurosis (LCA) is the most common genetic cause of congenital visual impairment in infants and children. Patients with LCA who harbor RPE65 mutations exhibit a deficiency in photoreceptor rhodopsin, leading to severe night blindness and visual impairment following birth. Since either gene replacement therapy or anti-apoptosis therapy alone cannot maintain both functional and morphological normality for a long time in the animal model, we propose a robust treatment strategy, that is, gene replacement therapy combined with anti-apoptotic therapy to protect photoreceptors from further degeneration while compensating for lost RPE65 function. Here, rd12 mice were injected subretinally at postnatal day 14 with four vector administrations, respectively. At 6 months after treatment, it was discovered that injection of three vectors, AAV8 (Y733F)-CBA-hRPE65, AAV8(Y733F)-CBA-hRPE65-BCL-2-L10 and mixture of half-dose AAV8(Y733F)-CBA-hRPE65 and half-dose AAV8 (Y733F)-CBA-BCL-2-L10, could partially restore the visual function of rd12 mice. Meanwhile, these treated eyes also exhibited a thicker outer nuclear layer (ONL) structure. However, despite the fact that the eyes of rd12 mice injected with the AAV8 (Y733F)-CBA-BCL-2-L10 vector displayed a slightly thicker ONL structure compared to untreated eyes, the visual function of the treated eyes did not recover. Continuing the observation period to 12 months after treatment, we found that compared to rd12 mice at 6-month post-treatment, rd12 mice injected with AAV8 (Y733F)-CBA-hRPE65 or mixture of half-dose AAV8(Y733F)-CBA-hRPE65 and half-dose AAV8 (Y733F)-CBA-BCL-2-L10 exhibited varying degrees of decline in both visual function and ONL thickness. However, in the case of rd12 mice injected with the AAV8(Y733F)-CBA-hRPE65-BCL-2-L10 vector, the ONL thickness remains consistent at both 6 and 12 months after treatment. These mice continued to maintain a relatively strong visual function and showed restoration in the levels of RPE65 and Rhodopsin protein expression. Our findings illustrate that early postnatal treatment with AAV vectors containing both the hRPE65 gene and the Bcl-2L10 anti-apoptotic gene provide enhanced and sustained retinal protection.

Vitreal Delivery of AAV Vectored Cnga3 Restores Cone Function in CNGA3-/-/Nrl-/- Mice, an All-Cone Model of CNGA3 Achromatopsia.

AAV-mediated Human CNGB3 Restores Cone Function in an All-Cone Mouse Model of CNGB3 Achromatopsia.

Gene Therapy Rescues Cone Structure and Function in the 3-Month-oldrd12mouse: A Model for Midcourse RPE65 Leber Congenital Amaurosis

Gene-based Therapy in a Mouse Model of Blue Cone Monochromacy

AAV-mediated Transfer of RhoA Shrna and CNTF Promotes Retinal Ganglion Cell Survival and Axon Regeneration

Generation of Nonhuman Primate Model of Cone Dysfunction Through in Situ AAV-Mediated CNGB3 Ablation

Gene augmentation therapy to rescue degenerative photoreceptors in a Cwc27 mutant mouse model

RNA Interference Gene Therapy in Dominant Retinitis Pigmentosa and Cone-Rod Dystrophy Mouse Models Caused by GCAP1 Mutations

Extended functional rescue following AAV gene therapy in a canine model of LRIT3-congenital stationary night blindness

RNAi-mediated Gene Suppression in a GCAP1(L151F) Cone-Rod Dystrophy Mouse Model.

Efficient retinal ganglion cells transduction by retro-orbital venous sinus injection of AAV-PHP.eB in mature mice

AAV-mediated gene augmentation therapy of CRB1 patient-derived retinal organoids restores the histological and transcriptional retinal phenotype

AAV dose-dependent transduction efficiency in retinal ganglion cells and functional efficacy of optogenetic vision restoration

Delivery of Nvegfi Using AAV8 for the Treatment of Neovascular Age-Related Macular Degeneration

Validation and Safety of Visual Restoration by Ectopic Expression of Human Melanopsin in Retinal Ganglion Cells.

<i>AAV8</i>-Mediated Gene Therapy Rescues Retinal Degeneration Phenotype in a <i>Tlcd3b</i> Knockout Mouse Model

AAV-mediated Expression of CNTF Promotes Long-Term Survival and Regeneration of Adult Rat Retinal Ganglion Cells

Unlocking therapeutic potential: dual gene therapy for ameliorating the disease phenotypes in a mouse model of RPE65 Leber congenital amaurosis

Cooperative Effects of Bcl-2 and Aav-Mediated Expression of Cntf on Retinal Ganglion Cell Survival and Axonal Regeneration in Adult Transgenic Mice

Scaav2-Mediated C3 Transferase Gene Therapy in a Rat Model with Retinal Ischemia/Reperfusion Injuries

Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse